BCL2L1 and diabetes mellitus: Interestingly, the pharmacological inhibition of Bcl-2 by the ABT-737 Bcl-2/Bcl-xL inhibitor or the Bcl-2-specific inhibitor ABT-199 eliminated senescent β-cells in NOD mice, preventing diabetes development in this model without affecting the immune cell population or non-senescent β-cells [195].